TNFRSF17 and Miyoshi myopathy: Based on the pathogenic role of BCMA via the activation of B cells in several autoimmune rheumatic disorders and the success of anti-BCMA CAR-T products in MM, various clinical trials are ongoing examining the safety and efficacy of these products in this field (Supplementary Materials, Table S2) [77].